CLIA Kit for Connective Tissue Growth Factor (CTGF)
CCN2; HCS24; IGFBP8; NOV2; Insulin-Like Growth Factor-Binding Protein 8; Hypertrophic Chondrocyte-Specific Protein 24; CCN Family Member 2
- Product No.SCA010Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length2h, 40min
- Detection Range5.49-4000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 1.99pg/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
For more details, please contact local distributors! US$ 912
For more details, please contact local distributors! US$ 4104
For more details, please contact local distributors! US$ 7752
For more details, please contact local distributors! US$ 63840
For more details, please contact local distributors!
This assay has high sensitivity and excellent specificity for detection of Connective Tissue Growth Factor (CTGF).
No significant cross-reactivity or interference between Connective Tissue Growth Factor (CTGF) and analogues was observed.
Matrices listed below were spiked with certain level of recombinant Connective Tissue Growth Factor (CTGF) and the recovery rates were calculated by comparing the measured value to the expected amount of Connective Tissue Growth Factor (CTGF) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Connective Tissue Growth Factor (CTGF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Connective Tissue Growth Factor (CTGF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Connective Tissue Growth Factor (CTGF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|Substrate A||1×10mL||Substrate B||1×2mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.
|Journal of Orthopaedic Research||Promotion of bone formation by naringin in a titanium particle-induced diabetic murine calvarial osteolysis model PubMed: 19824055|
|World Journal of Gastroenterology||Connective tissue growth factor hammerhead ribozyme attenuates human hepatic stellate cell function PubMed: PMC2726461|
|PLos One||Activation of JNK Signaling Mediates Connective Tissue Growth Factor Expression and Scar Formation in Corneal Wound Healing Plosone: 0032128|
|Clinical Biochemistry||Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy ScienceDirect: S0009912012000987|
|The Journal of Heart and Lung Transplantation||Connective tissue growth factor (CTGF/CCN2): A protagonist in cardiac allograft vasculopathy development? PubMed: S1053249812010121|
|Biomedical and Environmental Sciences||The Intervention Effect of Rosiglitozone in Ovarian Fibrosis of PCOS Rats Besjournal: Source|
|Disease Markers||Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis PubMed: 22846210|
|World Journal of Gastroenterology||Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis PubMed: PMC3351780|
|Journal of ethnopharmacology||Multitargeted protective effect of Abacopteris penangiana against carrageenan-induced chronic prostatitis in rats. Pubmed: 24211397|
|Radiation Oncology||Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy Ro-journal: Source|
|PLoS One.||Knock Out of S1P3 Receptor Signaling Attenuates Inflammation and Fibrosis in Bleomycin-Induced Lung Injury Mice Model Pubmed:Pmc4157792|
|European Journal of Heart Failure||Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models Pubmed:24464932|
|Bone||Connective Tissue Growth Factor is a Target of Notch Signaling in Cells of the Osteoblastic Lineage Pubmed:24792956|
|American Journal of Pathology||Disruption of collagen homeostasis can reverse established age-related myocardial fibrosis Pubmed:25701883|
|J Gastroenterol||Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis PubMed: 26190501|
|Life Sciences||Suppression of connective tissue growth factor mediates the renoprotective effect of Sitagliptin rather than Pioglitazone in type 2 diabetes mellitus Pubmed:27049870|
|International Journal of Molecular Sciences||TGF-β and Physiological Root Resorption of Deciduous Teeth. pubmed:28035998|
|Inflammation Research||Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy pubmed:27516211|
|Heart & Vessels||Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR pubmed:28004175|
|British Journal of Ophthalmology||The relationship between anti-vascular endothelial growth factor and fibrosis in proliferative retinopathy: clinical and laboratory evidence pubmed:27531356|
|Pathophysiology||Molecular mechanisms underlying fibrosis and elastin destruction in childhood interstitial lung diseases pubmed:27686729|
|Evidence-Based Complementary and Alternative Medicine||Cardioprotection against Heart Failure by Shenfu Injection via TGF-β/Smads Signaling Pathway pubmed:28698735|
|Heart and Vessels||Left ventricular reverse remodeling is not related to biopsy‑detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR 10.1007/s00380-016-0930-y|
|Cytokine||12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. pubmed:28460256|
|Advanced Healthcare Materials||Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. pubmed:29120858|